Workshop A – 9.00-12.00

Uncharted Waters – Overcoming Challenges in Implementing a Novel Conjugate Format

  • Obinna Ubah Principal Scientist, Elasmogen Ltd
  • Shu-Min Liu Chief Executive Officer, Shenzhen Enduring Biotech, Ltd.
  • Gokhan Yahioglu Co-Founder & Director R&D Medicinal Chemistry, Antikor

Synopsis

In the ever-evolving landscape of novel drug-conjugates, the pursuit of innovation often leads to unexplored territories. This workshop is designed for industry pioneers who dare to venture where no company has tread before. Offering an immersive exploration into the challenges that accompany the development of groundbreaking conjugates, join us to gain an understanding of the difficulties from conceptualisation to the clinic. Here we will unravel the journey of these biotech’s, tasked with reinventing the wheel in drug development.

Follow these pioneers on their journeys:

  • Discovery and origins of the novel conjugates
  • Analytical characterisation challenges of these unique molecules
  • Preclinical development and CMC considerations for first-in-class conjugates

Lunch – 12.00-1.00

Workshop B 1.00-4.00

Considerations for the Linker Choice When Working with Novel Format & Payload Conjugates

Synopsis

Dive deep into the intricate world of linker chemistry when working with novel payloads. Discover the cutting-edge advancements in linker technology and gain practical insights into optimising conjugate design for a dual-payload approach. Linkers are essential in determining the stability, specificity, and efficacy of conjugates, making informed decisions critical for the successful development of novel conjugate

drugs.

Delve into key considerations:

  • Uncover how to assess the compatibility of dual-payloads with a linker, ensuring both can be released without compromising the others stability and activity
  • Optimise linker cleavage to achieve simultaneous or sequential release of payloads